Isolation and properties of gene-modified mouse bcr-abl-transformed cells expressing various immunostimulatory factors

Neoplasma

Volumn 56, Issue 3, 2009, Pages 194-201

  Petrackova, M ^a   Sobotkova, E ^a   Duskova, M ^a   Jinoch, P ^a   Vonka, V ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Bcr Abl; CML; Cytokines; Gene modified tumour cells; HSV TK; Pathogenicity

Indexed keywords

AMINOPTERIN; BCR ABL PROTEIN; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYPOXANTHINE; INTERLEUKIN 12; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; THYMIDINE; THYMIDINE KINASE; CYTOKINE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA MODIFICATION; DRUG SENSITIVITY; ELECTROPORATION; FUSION GENE; GENE EXPRESSION; GENE ISOLATION; GENETIC TRANSFECTION; IMMUNOSTIMULATION; LEUKEMOID REACTION; MOUSE; NONHUMAN; PLASMID; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL TRANSFORMATION; GENETICS; MALE; ONCOGENE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; FUSION PROTEINS, BCR-ABL; GANCICLOVIR; GENES, ABL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; MALE; MICE; MICE, INBRED BALB C; THYMIDINE KINASE; TRANSFECTION;

EID: 85047684622     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_03_194     Document Type: Article

References (20)

1. Frazer R, Irvine AE, McMullin MF. Chronic Myeloid Leukaemia in The 21st Century. Ulster Med.J. 2007;76:8-17. (Pubitemid 46157342)
2. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat.Rev.Cancer 2005;5:172-183 doi:10.1038/nrc1567 (Pubitemid 40314949)
3. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol.Med. 2002;8(4 Suppl):S14-S18 doi:10.1016/S1471-4914(02)02305-5 (Pubitemid 34297073)
4. Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure. J.Manag.Care Pharm. 2007;13(8 Suppl A):8-12. (Pubitemid 350130893)
5. Bocchia M, Korontsvit T, Xu Q et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996;87:3587-3592 (Pubitemid 26129585)
6. Pinilla-Ibarz J, Korontsvit T, Zakhaleva V et al. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica. 2005;90:1324-1332 (Pubitemid 41503647)
7. He L, Feng H, Raymond A et al. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol.Immunother. 2001;50:31-40. doi:10.1007/PL00006680 (Pubitemid 32250044)
8. Zeng Y, Graner MW, Thompson S et al. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood. 2005;105:2016-2022 doi:10.1182/blood-2004-05-1915 (Pubitemid 40731786)
9. Zeng Y, Feng H, Graner MW et al. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood. 2003;101:4485-4491 doi:10.1182/blood-2002-10-3108 (Pubitemid 36857818)
10. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat.Rev.Cancer 2004;4:11-22. doi:10.1038/nrc1252
11. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J.Clin.Invest 2007;117:1175-1183 doi:10.1172/JCI31537 (Pubitemid 46718402)
12. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl.Acad.Sci.U.S.A 1988;85(23):9312-9316 doi:10.1073/pnas.85. 23.9312 (Pubitemid 19001887)
13. Sobotkova E, Ludvikova V, Petrackova M et al. Characteristic of two mouse bcr-abl-transformed cell lines: I. General properties of the cells. Folia Biol.(Praha) 2005;51:12-18.
14. Jelinek F, Sobotkova E, Vonka V. Characteristics of two mouse bcr-abl-transformed cell lines. II. Pathological lesions induced in mice. Folia Biol.(Praha). 2005;51:93-102.
15. Jinoch P, Zak R, Janouskova O et al. Immunization with live HPV-16-transformed mouse cells expressing the herpes simplex thymidine kinase and either GM-CSF or IL-2. Int.J. Oncol. 2003;23:775-783
16. Janouskova O, Sima P, Kunke D. Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection. Int.J.Oncol. 2003;22:569-577
17. Gaken J, Jiang J, Daniel K et al. Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron. Gene Ther. 2000;7(23):1979-1985 doi:10.1038/sj.gt.3301341 (Pubitemid 32036762)
18. Zolotukhin S, Potter M, Hauswirth WW et al. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J.Virol. 1996;70:4646-4654
19. Lakatosova-Andelova M, Jinoch P, Duskova M et al. Live cell vaccines expressing B7.1, monocyte chemoattractant protein 1 and granulocyte-macrophage colony stimulation factor derived from mouse HPV16-transformed cells. Int.J.Oncol. 2008;32:265-271 (Pubitemid 351176086)
20. Smahel M, Tejklova P, Smahelova J et al. Mutation in the immunodominant epitope of the HPV16 E7 oncoprotein as a mechanism of tumor escape. Cancer Immunol.Immunother. 2008;57:823-831 doi:10.1007/s00262-007-0418-9 (Pubitemid 351660126)